Active Not Recruiting PHASE1 INTERVENTIONAL 12-arm NCT05029882

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Sponsor: AbbVie

Conditions Advanced Solid Tumors Colorectal Cancer Gastroesophageal Adenocarcinoma Non-Small Cell Lung Cancer

Interventions ABBV-400 Bevacizumab Trifluridine/Tipiracil

Updated 29 times since 2021 Last updated: Oct 28, 2025 Started: Oct 13, 2021 Primary completion: Nov 30, 2027 Completion: Nov 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumors and Colorectal Cancer, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 29 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

29 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Mar 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 24 earlier versions

Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Mar 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE1
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1
Feb 2022 — May 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Feb 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcorcón, Spain , Aurora, United States , Badalona, Spain , Barcelona, Spain , Bordeaux, France , Busan, South Korea , Canton, United States , Changhua City, Changhua County, Taiwan , Cheongju-si, South Korea , Chicago, United States and 56 more locations